v3.26.1
Condensed Consolidated Statements of Convertible Preferred Stock & Stockholders' Equity - USD ($)
$ in Thousands
Total
Series A Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   150,000        
Beginning balance at Dec. 31, 2024   $ 142,820        
Temporary Equity            
Accretion of preferred stock dividends $ 1,322 $ 1,322        
Ending balance (in shares) at Mar. 31, 2025   150,000        
Ending balance at Mar. 31, 2025   $ 144,142        
Beginning balance (in shares) at Dec. 31, 2024     62,390,654      
Beginning balance at Dec. 31, 2024 21,729   $ 61 $ 1,177,045 $ (39) $ (1,155,338)
Increase (Decrease) in Stockholders' Equity            
Stock compensation expense 12,862     12,862    
Issuance of common stock in connection with ESPP (in shares)     21,875      
Issuance of common stock in connection with ESPP 854     854    
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)     494,853      
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units 2,226   $ 1 2,225    
Accretion of preferred stock dividends (1,322)     (1,322)    
Issuance of common stock upon completion of public offering, net of offering costs (in shares)     587,510      
Issuance of common stock upon completion of public offering, net of offering costs 32,108     32,108    
Foreign currency translation adjustment (2)       (2)  
Net unrealized loss on marketable securities (10)       (10)  
Net loss (49,498)         (49,498)
Ending balance (in shares) at Mar. 31, 2025     63,494,892      
Ending balance at Mar. 31, 2025 18,947   $ 62 1,223,772 (51) (1,204,836)
Beginning balance (in shares) at Dec. 31, 2025   132,500        
Beginning balance at Dec. 31, 2025 130,957 $ 130,957        
Temporary Equity            
Conversion of convertible securities (in shares)   (17,500)        
Conversion of Series A preferred stock redeemable to common stock   $ (17,351)        
Accretion of preferred stock dividends 1,104 $ 1,104        
Ending balance (in shares) at Mar. 31, 2026   115,000        
Ending balance at Mar. 31, 2026 $ 114,710 $ 114,710        
Beginning balance (in shares) at Dec. 31, 2025 67,205,321   67,205,321      
Beginning balance at Dec. 31, 2025 $ 139,069   $ 67 1,491,675 (796) (1,351,877)
Increase (Decrease) in Stockholders' Equity            
Stock compensation expense 23,099     23,099    
Issuance of common stock in connection with ESPP (in shares)     15,875      
Issuance of common stock in connection with ESPP 1,251     1,251    
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)     936,949      
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units 6,097   $ 2 6,095    
Tax withholding on vesting of restricted stock (in shares)     (77,643)      
Tax withholding on vesting of restricted stock (8,458)     (8,458)    
Conversion of Series A preferred stock redeemable to common stock (in shares)     364,582      
Conversion of convertible securities 17,351     17,351    
Accretion of preferred stock dividends (1,104)     (1,104)    
Foreign currency translation adjustment 1,784       1,784  
Net unrealized loss on marketable securities (544)       (544)  
Net loss $ (55,639)         (55,639)
Ending balance (in shares) at Mar. 31, 2026 68,445,084   68,445,084      
Ending balance at Mar. 31, 2026 $ 122,906   $ 69 $ 1,529,909 $ 444 $ (1,407,516)